Physician profile
David Miller
NPI 1265430797
$205,922.86
in general payments reported to CMS, 2019-2025
54 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $16K · 2021: $43K · 2022: $49K · 2023: $26K · 2024: $27K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Food and Beverage: $22K · Consulting Fee: $10K · Travel and Lodging: $4,691 · Education: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,173.75 |
| Food and Beverage | $22,402.37 |
| Consulting Fee | $10,110.00 |
| Travel and Lodging | $4,691.09 |
| Education | $511.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $95,475.95 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Astrazeneca Pharmaceuticals Lp | $53,978.62 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,502.17 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Mylan Specialty L.P. | $9,769.73 | 2019-2024 | Yupelri |
| Amgen INC. | $5,127.56 | 2022-2025 | Tezspire |
| Electromed, INC. | $4,431.16 | 2019-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $4,211.56 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $3,358.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $2,953.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| United Therapeutics Corporation | $2,559.33 | 2019-2025 | Tyvaso, Orenitram, Remodulin |
| Verona Pharma, INC. | $1,759.38 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $1,177.16 | 2019-2025 | Winrevair, Belsomra, Verquvo |
| Regeneron Healthcare Solutions, INC. | $1,135.79 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $1,075.02 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Jazz Pharmaceuticals INC. | $933.21 | 2019-2025 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $881.96 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $812.01 | 2020-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $653.03 | 2020-2025 | Glassia |
| Genzyme Corporation | $628.07 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $490.69 | 2019-2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $429.84 | 2019-2022 | |
| Baxter Healthcare | $319.89 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $300.56 | 2019-2021 | |
| Viatris Specialty LLC | $282.69 | 2025 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $275.27 | 2019-2023 | |
| Philips North America LLC | $272.86 | 2019-2025 | Vest Therapy Und |
| Axsome Therapeutics, INC. | $271.80 | 2022-2025 | Sunosi |
| Genentech USA, INC. | $246.56 | 2019-2020 | |
| Shire North American Group INC | $188.35 | 2019 | |
| Inspire Medical Systems, INC. | $137.82 | 2024-2025 | Inspire |
| Octapharma USA, INC. | $123.86 | 2020 | |
| Allergan, INC. | $115.38 | 2019-2020 | |
| Lilly USA, LLC | $104.04 | 2025 | Zepbound |
| Pfizer INC. | $85.05 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $83.63 | 2022-2025 | Quviviq, Quviviq |
| Mallinckrodt Hospital Products INC. | $82.33 | 2020 | |
| Vifor Pharma, INC. | $76.14 | 2024 | Zemaira |
| Avadel Cns Pharmaceuticals, LLC | $73.53 | 2025 | Lumryz |
| Azurity Pharmaceuticals, INC. | $72.64 | 2023-2025 | Horizant, Horizant |
| Medtronic Vascular, INC. | $70.74 | 2019 | |
| Abbvie INC. | $64.66 | 2021-2023 | |
| Mallinckrodt Enterprises LLC | $43.04 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.18 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $40.59 | 2023-2024 | Purified Cortrophin Gel |
| Eisai INC. | $29.01 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.86 | 2019-2021 | |
| Phadia US INC. | $23.82 | 2023 | Immunocap |
| Boston Scientific Corporation | $23.72 | 2021 | |
| Vapotherm INC | $22.20 | 2022 | |
| Portola Pharmaceuticals, LLC | $16.67 | 2020 | |
| Ethicon US, LLC | $15.75 | 2019 | |
| Gilead Sciences, INC. | $15.73 | 2021 | |
| Nabriva Therapeutics, Plc | $15.48 | 2020 | |
| Circassia INC. | $15.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.